Deep brain stimulation (DBS) is currently being used as a treatment for symptoms of Parkinson's disease (PD). Tracking symptom severity progression and deciding the optimal stimulation parameters for people with PD is extremely difficult. This study presents a sensor system that can quantify the three cardinal motor symptoms of PD - rigidity, bradykinesia and tremor. The first phase of this study assesses whether data recorded from the system during physical examinations can be used to correlate to clinician's severity score using supervised machine learning (ML) models. The second phase concludes whether the sensor system can distinguish differences before and after DBS optimisation by a clinician when Unified Parkinson's Disease Rating Scale (UPDRS) scores did not change. An average accuracy of 90.9 % was achieved by the best ML models in the first phase, when correlating sensor data to clinician's scores. Adding on to this, in the second phase of the study, the sensor system was able to pick up discernible differences before and after DBS optimisation sessions in instances where UPDRS scores did not change.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/ICORR.2017.8009462 | DOI Listing |
Acad Radiol
December 2024
Mallinckrodt Institute of Radiology, Washington University in Saint Louis, St. Louis, MO (A.N.). Electronic address:
IUBMB Life
January 2025
Cheerland Watson Precision Medicine Ltd, Shenzhen, China.
Parkinson's disease (PD), characterized by progressive degeneration of dopaminergic neurons in substantia nigra, has no disease-modifying therapy. Mesenchymal stem cell (MSC) therapy has shown great promise as a disease-modifying solution for PD. Induced pluripotent stem cell-derived MSC (iMSC) not only has stronger neural repair function, but also helps solve the problem of MSC heterogeneity.
View Article and Find Full Text PDFBrain Behav
January 2025
Department of Biomedical Engineering, Meybod University, Meybod, Iran.
Purpose: A debilitating and poorly understood symptom of Parkinson's disease (PD) is freezing of gait (FoG), which increases the risk of falling. Clinical evaluations of FoG, relying on patients' subjective reports and manual examinations by specialists, are unreliable, and most detection methods are influenced by subject-specific factors.
Method: To address this, we developed a novel algorithm for detecting FoG events based on movement signals.
Brain Behav
January 2025
Department of Neurology, Sichuan Taikang Hospital, Chengdu, Sichuan, China.
Background: Previous studies have confirmed the significant role of cathepsins in the development of neurodegenerative diseases. We aimed to determine whether genetically predicted 10 cathepsins may have a causal effect on Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
Methods: We conducted a two-sample bidirectional Mendelian randomization (MR) study using publicly available data from genome-wide association study (GWAS) to assess the causal associations between 10 cathepsins and three neurodegenerative diseases, including AD, PD, and ALS.
J Neurol Sci
December 2024
James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.
Introduction: Daytime sleepiness, reported in about 50 % of patients with Parkinson's disease (PD), is associated with high morbidity, poor quality of life and increased risk for accidents. While an association between dysautonomia and daytime sleepiness in early, de-novo PD has been reported, our understanding of the role of medications, cognitive status and co-morbidites on this relationship is inadequate.
Methods: Data were analyzed from the prospective Cincinnati Cohort Biomarkers Program.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!